
TTPH
Healthcare · Biotechnology · $16.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2020
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 7, 2020 | Time not confirmed | -1.63 | -1.31 | +19.6% |
| Mar 12, 2020 | Time not confirmed | -5.68 | -1.15 | +79.8% |
| Nov 13, 2019 | Time not confirmed | -6.80 | -6.00 | +11.8% |
| Aug 9, 2019 | Time not confirmed | -7.47 | -8.40 | -12.4% |
| May 9, 2019 | Time not confirmed | -7.88 | -7.20 | +8.6% |
| Mar 13, 2019 | Time not confirmed | -8.10 | -8.00 | +1.2% |
| Nov 7, 2018 | Time not confirmed | -7.28 | -7.40 | -1.6% |
| Aug 1, 2018 | Time not confirmed | -7.36 | -3.60 | +51.1% |
| May 2, 2018 | Time not confirmed | -8.44 | -8.40 | +0.5% |
| Mar 5, 2018 | Time not confirmed | -12.71 | -9.20 | +27.6% |
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant…